Zeynep Birsin Özçakar

Prof. Dr. Zeynep Birsin Özçakar

orcid

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 February 2009 in Rheumatology
Verified
Journal Article
Open access
PDF file
FYFatoş Yalçınkaya
Fatoş Yalçınkaya
SÖSeza Özen
Seza Özen
ZÖZeynep Birsin Özçakar
Zeynep Birsin Özçakar
NANuray Aktay
Nuray Aktay
NÇNilgün Çakar
Nilgün Çakar
ABAyşin Bakkaloğlu
Ayşin Bakkaloğlu
Objectives. Several sets of criteria mainly for adults have been proposed for the diagnosis of FMF. The aim of the present study is to validate the most widely used diagnostic ‘Tel Hashomer’ criteria in children and to establish a new set of criteria for use in childhood. Methods. The study group consisted of 170 recently diagnosed FMF patients who had mutations at both alleles. They were interviewed about the presence of 35 features and manifestations of FMF at the time of diagnosis. Controls were consecutive patients without FMF (n = 141) who had episodes of fever and clinical features mimicking that of FMF. The diagnostic performance of the candidate features was assessed by multiple logistic regression analysis. Results. The sensitivity and specificity of Tel Hashomer criteria in our study group were 98.8 and 54.6%, respectively. The multiple logistic regression analysis showed that 5 (fever, abdominal pain, chest pain, arthritis and family history of FMF) of the 35 candidate criteria discriminate FMF from controls with a sensitivity and specificity of 88.8 and 92.2%, respectively. The presence of two or more of these five criteria diagnosed FMF with a sensitivity of 86.5% and a specificity of 93.6%. Conclusion. It was demonstrated that although the Tel Hashomer criteria were successful in diagnosing the FMF patients in childhood, its specificity was definitely low in children. The new set of criteria has a high sensitivity and specificity for the diagnosis of FMF and is practical to use on an everyday basis.

1 June 2016 in Cell
Verified
Journal Article
Closed access
VSVanja Sisirak
Vanja Sisirak
BSBenjamin Sally
Benjamin Sally
VDVivette D’aGati
Vivette D’aGati
WMWilnelly Martinez-Ortiz
Wilnelly Martinez-Ortiz
ZÖZeynep Birsin Özçakar
Zeynep Birsin Özçakar
BRBoris Reizis
Boris Reizis

1 April 2015 in Clinical Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
PDF file
ATAgnes Trautmann
Agnes Trautmann
MBMonica Bodria
Monica Bodria
FOFatih Ozaltin
Fatih Ozaltin
AGAlaleh Gheissari
Alaleh Gheissari
AMAnette Melk
Anette Melk
FSFranz Schaefer
Franz Schaefer
Background and objectives Steroid-resistant nephrotic syndrome is a rare kidney disease involving either immune-mediated or genetic alterations of podocyte structure and function. The rare nature, heterogeneity, and slow evolution of the disorder are major obstacles to systematic genotype-phenotype, intervention, and outcome studies, hampering the development of evidence-based diagnostic and therapeutic concepts. To overcome these limitations, the PodoNet Consortium has created an international registry for congenital nephrotic syndrome and childhood-onset steroid-resistant nephrotic syndrome. Design, setting, participants, & measurements Since August of 2009, clinical, biochemical, genetic, and histopathologic information was collected both retrospectively and prospectively from 1655 patients with childhood-onset steroid-resistant nephrotic syndrome, congenital nephrotic syndrome, or persistent subnephrotic proteinuria of likely genetic origin at 67 centers in 21 countries through an online portal. Results Steroid-resistant nephrotic syndrome manifested in the first 5 years of life in 64% of the patients. Congenital nephrotic syndrome accounted for 6% of all patients. Extrarenal abnormalities were reported in 17% of patients. The most common histopathologic diagnoses were FSGS (56%), minimal change nephropathy (21%), and mesangioproliferative GN (12%). Mutation screening was performed in 1174 patients, and a genetic disease cause was identified in 23.6% of the screened patients. Among 14 genes with reported mutations, abnormalities in NPHS2 (n=138), WT1 (n=48), and NPHS1 (n=41) were most commonly identified. The proportion of patients with a genetic disease cause decreased with increasing manifestation age: from 66% in congenital nephrotic syndrome to 15%–16% in schoolchildren and adolescents. Among various intensified immunosuppressive therapy protocols, calcineurin inhibitors and rituximab yielded consistently high response rates, with 40%–45% of patients achieving complete remission. Confirmation of a genetic diagnosis but not the histopathologic disease type was strongly predictive of intensified immunosuppressive therapy responsiveness. Post-transplant disease recurrence was noted in 25.8% of patients without compared with 4.5% (n=4) of patients with a genetic diagnosis. Conclusions The PodoNet cohort may serve as a source of reference for future clinical and genetic research in this rare but significant kidney disease.

10 May 2013 in Arthritis & Rheumatism
Verified
Journal Article
Open access
PDF file
ZÖZeynep Birsin Özçakar
Zeynep Birsin Özçakar
JFJoseph Foster
Joseph Foster
ODOscar Diaz‐Horta
Oscar Diaz‐Horta
OKOzgur Kasapcopur
Ozgur Kasapcopur
YFYao‐Shan Fan
Yao‐Shan Fan
MTMustafa Tekin
Mustafa Tekin
Objective: Hypocomplementemic urticarial vasculitis syndrome (HUVS) is characterized by recurrent urticaria along with dermal vasculitis, arthritis, and glomerulonephritis. Systemic lupus erythematosus (SLE) develops in >50% of patients with HUVS, although the pathogenesis is unknown. The aim of this study was to identify the causative DNA mutations in 2 families with autosomal‐recessive HUVS, in order to reveal the pathogenesis and facilitate the laboratory diagnosis.Methods: Autozygosity mapping was combined with whole‐exome sequencing.Results: In a family with 3 affected children, we identified a homozygous frameshift mutation, c.289_290delAC, inDNASE1L3. We subsequently identified another homozygousDNASE1L3mutation leading to exon skipping, c.320+4delAGTA, in an unrelated family. The detected mutations led to loss of function, via either nonsense‐mediated messenger RNA decay or abolished endonuclease activity, as demonstrated by a plasmid nicking assay.Conclusion: These results show that HUVS is caused by mutations inDNASE1L3, encoding an endonuclease that previously has been associated with SLE.

30 May 2010 in Pediatric Nephrology
Verified
Journal Article
Closed access
PDF file
OGon behalf of The Turkish Society for Pediatric Nephrology Acute Kidney Injury Study Group
on behalf of The Turkish Society for Pediatric Nephrology Acute Kidney Injury Study Group
ADAli Duzova
Ali Duzova
ABAysin Bakkaloglu
Aysin Bakkaloglu
MKMukaddes Kalyoncu
Mukaddes Kalyoncu
HPHakan Poyrazoglu
Hakan Poyrazoglu
FSFerah Sonmez
Ferah Sonmez

19 April 2018 in Clinical Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
PDF file
LMLaura Massella
Laura Massella
DMDjalila Mekahli
Djalila Mekahli
DPDušan Paripović
Dušan Paripović
LPLarisa Prikhodina
Larisa Prikhodina
NGNathalie Godefroid
Nathalie Godefroid
FEFrancesco Emma
Francesco Emma
Background and objectives: Autosomal dominant polycystic kidney disease is the most common inheritable kidney disease, frequently thought to become symptomatic in adulthood. However, patients with autosomal dominant polycystic kidney disease may develop signs or symptoms during childhood, in particular hypertension. Although ambulatory BP monitoring is the preferred method to diagnose hypertension in pediatrics, data in children with autosomal dominant polycystic kidney disease are limited. Design, setting, participants, & measurements: Our retrospective multicenter study was conducted to collect ambulatory BP monitoring recordings from patients with autosomal dominant polycystic kidney disease age 1 cm per kidney and daytime hypertension (odds ratio, 1.70; 95% confidence interval, 1.21 to 2.4; P=0.002), nighttime hypertension (odds ratio, 1.31; 95% confidence interval, 1.05 to 1.63; P=0.02), or 24-hour hypertension (odds ratio, 1.39; 95% confidence interval, 1.08 to 1.81; P=0.01). Kidney length, expressed as SD score, was also significantly associated with nighttime hypertension (odds ratio, 1.23; 95% confidence interval, 1.06 to 1.42; P=0.10). Conclusions: These data indicate high prevalence of hypertension in children with autosomal dominant polycystic kidney disease starting at young ages.